CD274 and gastroesophageal junction adenocarcinoma: In advanced gastric or gastroesophageal junction adenocarcinoma, PD-L1 expression is assessed using the FDA-approved PD-L1 IHC 22C3 pharmDx assay and a combined positive score (CPS) (2).